BSC BioNEST Bio-Incubator

United Nations Educational, Scientific and Cultural Organization

क्षेत्रीय जैव प्रौद्योगिकी केन्द्र
Regional Centre for Biotechnology

INNOVATION ALMANAC 2025

Celebrating the Spirit of Bio-Innovation

BSC BioNEST Bio-Incubator
Regional Centre for Biotechnology, Faridabad

3rd Milestone, Faridabad-Gurugram Expressway, Faridabad, Haryana 121001

0129-2848625/606

bbb@rcb.res.in

CONTENT

Forewords from Leadership

Words That Inspire: Message from Secretary, DBT and Chairman, BIRAC

Dear Esteemed Stakeholders,

It is with a great sense of satisfaction & pleasure that I write foreward for the BBB–RCB Innovation Almanac showcasing the pioneering spirit and scientific entrepreneurship fostered at the BSC BioNEST Bio-Incubator (BBB) at the Regional Centre for Biotechnology (RCB).

The Department of Biotechnology has played a transformative role in shaping India's biotech landscape by advancing high-quality research, nurturing talent, and enabling innovation. Innovation and entrepreneurship form the cornerstone of today's rapidly evolving biotechnology ecosystem. With Biotechnology Industry Research Assistance Council (BIRAC) leading the nation's innovation efforts, BBB at RCB serves as a dynamic hub supporting early-stage biotech ventures through essential resources, networks, and platforms that enable real-world solutions and strengthen India's bioeconomy.

The DBT–BIRAC BioNEST program is strengthening India's innovation ecosystem and driving growth across healthcare, agriculture, biopharma, and industrial biotechnology. BBB is poised to play a pivotal role in this progress, fuelling economic growth, strengthening national capabilities, and shaping a future where innovation drives healthier communities and a more sustainable world.

The Almanac showcases the innovative achievements of startups across healthcare, agriculture, sustainable manufacturing, and AI-driven life sciences. It well captures the energy and creativity of India's innovators especially those improving access, affordability, and quality of healthcare while driving India's emergence as a global bio-pharma hub for health innovation.

As India's bio-entrepreneurial landscape continues to grow rapidly, we look forward to building on these achievements and nurturing a collaborative ecosystem where ideas can scale, and breakthroughs can flourish to empower the next generation of innovative science leaders.

Best Wishes!

Rajesh S. Gokhale
Secretary

Forewords from Leadership

Words That Inspire: Message from Managing Director, BIRAC

Dear Esteemed Members of the Innovation Ecosystem,

I am delighted to present the inaugural edition of the Innovation Almanac, an initiative that reflects the growing strength and maturity of India's biotechnology innovation ecosystem. This publication highlights the startups nurtured at the BSC BioNEST Bio-Incubator (BBB) at the Regional Centre for Biotechnology (RCB), each representing a unique blend of scientific excellence, entrepreneurial drive, and a commitment to delivering impactful solutions.

At BIRAC, our vision has consistently been to empower emerging innovators, support breakthrough ideas, and accelerate the translation of research into viable technologies that benefit society. The startups featured in this almanac embody this spirit. Their work spans a broad spectrum from advanced diagnostics and biopharmaceutical development to sustainable biomanufacturing, food and nutrition technologies, and AI-enabled life sciences. Their innovations hold the promise to address some of the nation's most pressing challenges, strengthen India's bioeconomy, and contribute to global scientific advancement.

RCB, as an Institution of National Importance under the Department of Biotechnology, has played a pivotal role in fostering a robust environment where high-quality research, skilled talent development, and entrepreneurship converge. BBB, with its state-of-the-art infrastructure, technical expertise, and supportive ecosystem, has further strengthened this foundation, enabling young ventures to grow with confidence and clarity of purpose.

I encourage investors, industry leaders, academic institutions, and innovation partners to engage with the startups featured here. Your collaboration whether through mentorship, validation, funding, or strategic partnerships can accelerate their journey from early-stage ideas to transformative, market-ready technologies.

I commend the leadership and team at RCB and BBB for their dedication in nurturing these startups and for curating this comprehensive almanac. Their efforts reflect a deep commitment to building an inclusive, vibrant, and future-ready innovation ecosystem.

My best wishes to all the innovators showcased in this edition. May your ideas continue to inspire, evolve, and contribute meaningfully to India's scientific and economic growth.

Jitendra Kumar,
Managing Director

Forewords from Leadership

Words That Inspire: Message from Executive Director, RCB

Dear Esteemed Partners, Mentors, Investors, and Collaborators,

It is my privilege to present the inaugural edition of the Innovation Almanac, a compendium showcasing the emerging startups nurtured at the BSC BioNEST Bio-Incubator (BBB) at the Regional Centre for Biotechnology (RCB). It marks an important milestone in our ongoing efforts to build a vibrant and impactful biotechnology innovation ecosystem.

The Regional Centre for Biotechnology (RCB), an Institution of National Importance established by the Department of Biotechnology (DBT), Government of India, under the auspices of UNESCO as a Category II Centre, plays a central role in advancing biotechnology research, developing a skilled scientific workforce, and fostering innovation-driven enterprises. With a mandate that benefits not only India but also the wider South Asian region, the RCB leverages its UNESCO association to promote high-quality education, cutting-edge research, and global scientific collaboration.

RCB's vision is to create an environment in which science-driven entrepreneurs can transform ideas into solutions that address societal needs and strengthen India's growing bioeconomy. The incubator is a key pillar of this vision, enabling innovators to work across healthcare, agriculture, food innovation, sustainable biomanufacturing, and AI-enabled life sciences. The startups featured in this almanac embody the spirit of innovation. Their ideas reflect scientific rigor, creativity, and a clear commitment to addressing real world challenges.

I invite investors, collaborators, industry partners, and academic institutions to explore and engage with the innovators featured in this edition. Your mentorship, partnership, and support are invaluable in helping these young ventures scale their ideas into meaningful and impactful solutions.

I would also like to acknowledge the leadership and operational stewardship of our Chief Operating Officer and the dedicated efforts of her team, which have been instrumental in shaping the incubator's progress.

On behalf of the RCB, I extend my sincere gratitude to all our stakeholders for their encouragement and steadfast belief in our mission. Let us continue working together to strengthen India's innovation landscape and contribute to a healthier, more sustainable, and resource-efficient future.

Jai Hind!

Arvind K Sahu
Executive Director

Forewords from Leadership

Words That Inspire: Message from Chief Operations Officer, BBB

Dear Esteemed Stakeholders,

It is with great pride that I introduce to you the first edition of our Innovation Almanac, a curated showcase of promising startups incubated at the BSC BioNEST Bio-Incubator (BBB), Regional Centre for Biotechnology (RCB).

Backed by the vision of the Department of Biotechnology (DBT), Government of India, and nurtured through the support of BIRAC, our incubator has been home to a diverse array of entrepreneurs working at the frontiers of biotechnology, biopharma, advanced diagnostics, healthcare solutions, and sustainable innovation. Each profile included in this almanac reflects the spirit of creativity, scientific rigor, and social relevance.

This almanac is more than just a listing. It is a window into the future of Indian innovation. It brings forward the energy and ideas of entrepreneurs solving some of the most pressing challenges of our time. From breakthrough diagnostic tools to environmentally conscious materials, these startups are building technologies with the potential to scale and make meaningful impact.

I invite investors, collaborators, R&D partners, and institutions to engage with these innovators. Your continued support whether through strategic partnerships, funding, technology validation, or mentorship, is instrumental in translating ideas into viable, impactful solutions.

At BBB, we remain committed to building a dynamic ecosystem where early-stage innovations are empowered with the resources, networks, and platforms they need to grow. We are grateful to our stakeholders for their belief in this mission, and for enabling us to support the next generation of biotech entrepreneurs.

I am deeply appreciative of the dedicated BBB team whose commitment, passion, and hard work make this ecosystem possible and vibrant. Let us continue this journey of innovation together, expanding opportunities, catalysing change, and advancing a healthier, more sustainable world.

Best Wishes,

Suman Gupta
Chief Operations Officer

About BBB

A Launchpad for Next-Gen Biotech Startups

The BSC BioNEST Bio-Incubator (BBB) is established at Regional Centre for Biotechnology (RCB), which is an Institute of National Importance under the auspices of UNESCO. The BBB facility is managed and operated by RCB, and is supported by the DBT-BIRAC BioNEST scheme (Bio-Incubator Nurturing Entrepreneurship for Scaling Technologies). It has become a premier bio-incubation hub for young bio-entrepreneurs, helping them transform their innovative ideas into commercially viable products with significant medical and environmental impact. The BBB ecosystem, spanning 35,000 sq. ft. within the NCR Biotech Science Cluster, offers state-of-the-art facilities, including a central instrumentation facility, lab and culture spaces, and office suites. To date, BBB has supported around 75 startups working across diverse sectors such as diagnostics, healthcare, med-tech, industrial biotech, biopharma (vaccines and therapeutics), digital health, social impact, environmental sustainability, and agro-food technologies. Through our efforts, these startups have not only fostered innovation but have also created a significant impact on the economy.

To date, we have created over 425 jobs, generated more than ₹300 crores in startup revenue, and successfully brought 25+ products to market. At BBB, we remain committed to nurturing pioneering solutions that address today's challenges and shape a better tomorrow. Incubatees benefit from a wide range of services, including intellectual property support, business mentorship, strategic guidance, funding assistance, access to the network of mentors, and the Advanced Technology Platform Centre (ATPC) facilities.

The facility is located in NCR Biotech Science Cluster, Faridabad, which is just a 30-minute drive from Delhi & Gurugram. The ongoing programs focusing on entrepreneurship development are delivering positive outcomes by enhancing knowledge and awareness of startup culture, fostering a startup mind-set, encouraging innovation through startup challenges, expanding understanding of cutting-edge technologies, and providing crucial support to emerging startups.

Pioneering Tomorrow

Empowering Innovation, Enabling Impact

Mission

BBB is committed to fostering innovation and entrepreneurship in the field of biotechnology by serving as a dynamic launch pad for early-stage biotech ventures. Established with a vision to catalyse the growth of a vibrant biotech ecosystem in the National Capital Region (NCR), the incubator aims to:

- Accelerate the establishment of biotechnology startups by providing them with access to cutting-edge infrastructure, technical mentorship, business development support, and regulatory guidance. By bridging the gap between research and commercialization, BBB facilitates a faster journey from lab to market.
- Empower scientists, researchers, and innovators to transform their novel ideas and scientific breakthroughs into commercially viable technologies and scalable business models. The incubator nurtures entrepreneurial talent and supports the development of impactful solutions that address pressing healthcare, agricultural, and environmental challenges.

Through this mission, BBB strives to become a centre of excellence in translational research and biotech entrepreneurship, enabling the development of next-generation technologies while contributing to the national agenda of Atmanirbhar Bharat (self-reliant India) and global bio-innovation.

Vision

To be a leading hub of biotechnology innovation and entrepreneurship in India, driving impactful research translation and fostering the growth of biotech startups. BBB envisions a future where scientific ideas seamlessly evolve into successful enterprises that contribute to national development, improve human health, and address global challenges in healthcare, agriculture, and the environment.

By nurturing a culture of innovation, collaboration, and excellence, the incubator aspires to be a catalyst for building a sustainable and self-reliant bio economy.

Our Offerings

Incubation Services That Drive Success

At BBB, we provide comprehensive support to startups and individual entrepreneurs, tailored to their unique needs:

Our services are designed to accelerate the growth of startups and foster innovation, enabling them to scale efficiently and effectively in a competitive global market. The Bioincubator provides a comprehensive support system for deep-tech bio startups, offering access to BSL-3 labs, state-of-the-art research facilities, an animal house, and platforms like ATPC and IBDC. Startups benefit from funding facilitation, ethical approval support, IP and technical mentorship, and strategic networking. Situated within a vibrant life sciences cluster alongside premier institutes like RCB and THSTI, the incubator fosters interdisciplinary collaboration. This ecosystem empowers innovators to efficiently translate cutting-edge ideas into impactful biotech solutions.

Focus Areas

Shaping the Future, One Domain at a Time



Incubatees Domain of Work



Our Journey So Far

Milestones That Shaped Us



What Impact Has Been Created

Key Outcomes from the BBB Ecosystem

70+
Startups Incubated

425+
Direct jobs created

25+
Product/ Prototype developed

30+
Women-led startups

190 Cr+
Fund raised by Incubatee companies

90+
IP Filings

11
Seed Funding

5
Follow on Fundraising

30+
Secured Govt. Grants/ Awards

She Innovates, We Accelerate

Turning her vision into unstoppable momentum

- **Dr. Neetika Ashwani, Founder, Kriash MedTech Pvt. Ltd., honored with the Global Women in Business Leadership Award 2025 for outstanding contributions to healthcare innovation and entrepreneurship.**
- **Selected for the Stanford Seed Spark Program, gaining strategic insights to scale mission-driven healthcare innovations.**

- **Ms. Prathyusha Potharaju, Co-founder, Grailmaker Innovations Pvt. Ltd., finalist in the Bayer Women Entrepreneur Awards 2025, along with a €25,000 grant.**
- **Featured in Forbes 30 Under 30 Asia 2025 in the Social Impact category.**

She Innovates, We Accelerate

Turning her vision into unstoppable momentum

- **Ms. Sonia Madan, Co-founder, Intele Labs Pvt. Ltd.**
- **Honored with the Best Startup Award (Women Entrepreneur Category) at Global Bio-India 2024.**

Stellar Diagnostics India Pvt. Ltd. has developed the world's first rapid, low-cost triage lateral flow assay test for TB, undergoing multicentric clinical validation at four sites across India under ICMR's guidance.

Powering Progress: Women in Innovation

Empowering Women Founders, Fueling Change

BBB is proud to support and celebrate pioneering women entrepreneurs who are shaping the future of biotech innovation and making significant contributions to healthcare, sustainability, and social progress.





The All-Women Team of BBB

Empowering Innovation Through Leadership

BBB's operational and strategic engine is powered by an all-women leadership team - a rarity in the incubation landscape. This team blends scientific expertise, business acumen, and ecosystem know-how to create an inclusive and high-performance environment for biotech entrepreneurship.

Our Leadership Values:

- Representation in STEM – showcasing women's leadership in science, innovation, and policy
- Inclusive Ecosystem – fostering women-led startups (25 to date) and supporting gender diversity
- Holistic Mentorship – providing technical depth and market-oriented guidance
- Empowerment through Visibility – connecting women founders to global platforms

Suman Gupta
Chief Operations Officer

20+ years of corporate experience in pharmaceutical R&D with global MNCs. Skilled in project management and international collaborations. Currently leads BBB, nurturing biotech startups through strategic mentorship, operational leadership, and ecosystem development for research commercialization

Malvika Garg
Consultant (IP & Incubation)

15+ years of experience in drug discovery, IP management, and project management. Formerly with Ranbaxy and Daiichi Sankyo. Currently leads incubation activities and IP management, bringing strong expertise in bio-incubator operations to support biotech innovation and ecosystem development.

Kanchan Rawat
Consultant (Technical)

5+ years in research & bio-incubator management. She manages instrumentation facility, trains incubatees, supports startups, ensures biosafety/ethics compliance, and coordinates events to foster innovation.

Priyanka Khare
Senior Assistant

With a Master's in Political Science and 7+ years of experience, she manages administration, documentation, and coordination at BBB. A collaborative problem-solver who thrives on responsibility and new challenges.

Ecosystem Sponsors & Growth Enablers

Accelerators, Collaborations & Catalysts

जैव प्रौद्योगिकी विभाग
Department of Biotechnology
Ministry of Science & Technology
Government of India
सत्यमेव जयते

बाइरैक
इग्नाइट इनोवेट इंक्यूबेट
birac
Ignite Innovate Incubate

Bio-NEST

startupindia
SEED FUND SCHEME

DPIIT
#startupindia

Ministry of Micro, Small and Medium Enterprises,
Government of India
MSME
MICRO, SMALL & MEDIUM ENTERPRISES
सूक्ष्म, लघु एवं मध्यम उद्यम

STARTUP HARYANA
FIRST STEP OF SUCCESS

CSR Partner Driving Innovation

TechInvention
towards greater health equity

Catalyzing Growth Through Government Grants

Enabling breakthrough ideas with strategic financial support

Startup India Seed Fund Scheme (2022)

MSME Innovative Scheme (2023)

Early Translation Accelerator (ETA) Centre (2024)

Enabling Development & Growth of Enterprises (EDGE) (2025)

Startup India Seed Fund Scheme

Funding Support

- Total SISFS Grant Sanctioned: ₹3 Crore
- Startups Supported: 11 high-potential startups
- Support Mode: Grant/ Debt based funding and incubation support

Supported Startups

HeaLink

Translational Research & Innovations

PRO-ORTHO PERFECT

kriash

VeGen Labs
Redefining Drug Discovery

SHAKTI
Fashion meets safety

GRAILMAKER INNOVATIONS

EAST OCYON BIO

THRAFFORD

Ethnobio Deeptech Innovations Private Limited

MSME Innovative Scheme

Ministry of Micro, Small and Medium Enterprise
Government of India
MSME
MICRO, SMALL & MEDIUM ENTERPRISES

- RCB recognized as a Host Institute (HI)under the scheme in FY23
- Enables support for innovation and early-stage startups through the MSME Innovative Scheme

Hackathon 3.0 (For Women)

- **1 proposal approved and received ₹15 lakh funding**
- **Currently being incubated and mentored at BBB**

Hackathon 4.0 (For Young Innovators)

- **4 proposals approved; implementation will initiate post receipt of funds**

Hackathon 5.0 (for 18 to 60 years of age)

- **Proposals forwarded; final results awaited**

Supported Startups

kriash

Dr. Jayanti Kumari

Kumar Nischaya

Vanshika

Dr. Nita Sharma Das

Himanshu Rajpurohit

Strategic Programs

Nurturing Talent, Advancing Technology, Accelerating Startups

Awareness & Entrepreneurship Development

Programmes that ignite entrepreneurial aptitude and cultivate a startup mindset

IDEA - Ignite & Develop Entrepreneurial Aptitude

- Focus: Young Students / Researchers
- Themes: Innovation & Ideation, Entrepreneurship & Startup Mindset, Bio-Entrepreneurship Essentials, Leadership & Skill Building, Startup Ecosystem Exposure.
- Impact: Knowledge & awareness of startup culture

EMPOWER - Educating Minds & Promoting Ownership in Entrepreneurial Roles

- Focus: Innovators / Researchers / Young Minds
- Impact: Cultivating a strong entrepreneurial culture

Workshops & Technology Exposure

Hands-on learning programmes focused on advanced tools, technologies, and skills

LEARN - Latest Equipment & their Application useful in Research of Next-Gen

- Focus: Young Students / Researchers
- Workshop Themes: RT-PCR, upstream and downstream bioprocessing, ELISA, lateral flow immunoassay technologies, lyophilizer, data integrity etc.
- Impact: Awareness and understanding of cutting-edge technologies



Ideathon & Innovation Competitions

Challenge-based programmes that help participants convert ideas into startup opportunities

FINE – Foster Innovation & Nurture Entrepreneurship

- Focus: Researchers / Students / Budding Entrepreneurs
- Innovation Challenge: "SPARK" - A startup boost-up challenge based on real-world problem statements
- Impact: A boost-up platform empowering innovative minds to turn real problems into impactful startup solutions

Equipment Advancement & Industry Technology Roadshow Programmes

Enhancing research capabilities through technology demos and equipment expertise

TECH ROADSHOW – Technology Enhancement & Capability Hub

- Focus: Researchers, startups, incubator labs, vendor-led technology demonstrations (Bio-Rad, Thermo Fisher, HiMedia, Cytiva etc.)
- Impact: Exposure to the latest scientific instruments, hands-on training on advanced workflows, improved technical competency, and informed equipment adoption for high-quality R&D.

Strategic Alliances

Building Synergies to Accelerate Innovation

Hospital & Clinical Connectivity

Medanta

Redcliffe labs

Technology Transfer & Commercialization

FITT

BCIL

Academic & Research Collaborations

MANAV RACHNA vidyanatariksha

BENNETT UNIVERSITY THE TIMES GROUP

IISER KOLKATA

SGT UNIVERSITY

Government & Innovation Ecosystem

IIT Bombay SINE Business Incubator

BITS Pilani K K Birla Goa Campus

Pilani Innovation and Entrepreneurship Development Society

Current Incubatees

Fueling Transformative Impact Through Science-Driven Entrepreneurship









Graduated Incubatees

Pioneers Who Scaled New Heights After Incubation



Startup Success Stories

From Bench to Business: Spotlight on High-Impact Startups

Fueling the future of healthcare: East Ocyon Bio secures ₹36 Cr for Cell & Gene Therapy innovation.

- **"Dharaksha Ecosolutions raises ₹24.8 Cr to fuel sustainable growth."**
- **"Shark Tank India success: Dharaksha Ecosolutions clinches an all-shark deal."**

Startup Success Stories

From Bench to Business: Spotlight on High-Impact Startups

- **Won the India 5000 Best MSME Award 2024 for excellence in quality, customer satisfaction, and societal impact.**
- **Bagged the NASSCOM Emerge 50 Award 2024 in the Biotech & Nanotech category, recognizing deep-tech innovation.**

Fueling the future: Vegen Labs secures ₹ 3.8 Cr BIRAC funding

Startup Success Stories

From Bench to Business: Spotlight on High-Impact Startups

Early success: PrecizionIQ secures ₹2.1 Cr Pre-seed funding

TechInvention Lifecare Pvt. Ltd. featured in the prestigious Forbes India SELECT 200 list at DGEMS 2024, for transformative global business potential.

Startup Success Stories

From Bench to Business: Spotlight on High-Impact Startups

Translational Research & Innovations Pvt. Ltd. launched India's first vegan fish feed at Global Bio-India (GBI) 2024.

- **HeaLink – Third AI Platforms is Ayushman Bharat Digital Mission (ABDM) compliant.**
- **Approved by the National Health Authority (NHA).**

Startup Success Stories

From Bench to Business: Spotlight on High-Impact Startups

Anziam Bio Pvt. Ltd. received CDSCO license for Class C & Class D medical devices.

- **Sleepiz One+ Connect launched the world's first remote, contactless, radar-based respiration monitor and medical device.**
- **Raised ₹57.6 Cr in funding to scale its innovation.**

Explore the journeys of visionary startups driving innovation, improving lives, and shaping the future of healthcare and technology

Innovating for a Healthier Tomorrow

A curated showcase of pioneering startups transforming healthcare and technology in India

Environment Biotechnology

Packaging Material Made Out of Crop Stubble Waste

Application

Eco-friendly biodegradable packaging developed from agricultural waste to replace conventional plastic packaging materials.

COMPANY NAME	FOUNDERS' NAME
Dharaksha Ecosolutions Pvt Ltd	**Arpit Dhupar**
TRL- 7	**INTELLECTUAL PROPERTY**
Revenue generation stage	**To be filed**

ABOUT THE TECHNOLOGY

We are developing an innovative in-vitro bioengineering technique to combat air pollution in Northern India by converting rice stubble—typically burned and a major contributor to seasonal smog—into a mycelium-based biodegradable biocomposite. This eco-friendly material is created through a stepwise process involving tissue culture, liquid fermentation, substrate inoculation, and sterile shaping. To address its limited durability in extreme weather, we are also formulating a natural protective coating to extend shelf life and prevent contamination. This approach offers a sustainable alternative to stubble burning while enabling scalable production of biodegradable materials.

USP

Fully Customizable Design

- Mycelium packaging can be molded into any shape or size
- Ideal for cosmetics, electronics, and premium packaging
- Offers greater flexibility compared to fixed-mold competitors

High Consistency in Customization

- Maintains uniform quality across customized units
- Addresses a major limitation in the current mycelium packaging market

Natural Shelf-Life Enhancing Coating

- Proprietary bio-based coating prevents moisture absorption
- Extends shelf life without plastic or synthetic additives
- Solves a key challenge faced by other biodegradable solutions

Incubated at BBB I RCB

https://www.dharaksha.com/

PROBLEM ADDRESSED

Dharaksha Ecosolutions provides a sustainable alternative to thermocol, a plastic material that persists in the environment up to 20 times longer than our biodegradable solution. Designed for eco-conscious packaging, our product offers high durability with zero breakage and can be customized in shape and size. By upcycling agricultural waste as raw material, it supports a circular economy and delivers an organic, visually appealing alternative to conventional plastic-based packaging

FUNDS RAISED/ACHIEVEMENTS

- Startup India Seed Fund Scheme - 6 Lakhs
- PUSA UPJA - 25 Lakhs
- Krishi Mangal 2.0 - Cisco India CSR & Social Alpha 42 Lakhs
- Angels - 3.98 Cr;
- VC Funding by Momentum capital, Aavana capital and rainmatter foundation – 25 Cr
- NBEC 2021
- IPCH - INDIA PLASTIC HACKATHON
- Nidhi EIR & Prayas

END USERS/CUSTOMERS

- Brands and manufacturers in consumer goods and electronics
- Food & beverage companies seeking sustainable packaging alternatives
- E-commerce businesses looking for eco-friendly shipping protection
- Health and wellness product companies
- Designers and artisans creating sustainable interior décor and artefacts
- Organizations investing in eco-friendly gifting and promotional products

Allogeneic Cell & Gene Therapy

India's First Allogeneic Cell Therapy company developing Indigenous **CAR-NK & CAR Gamma Delta T Cell** technology platform.

Application

Transforming the treatment landscape of Solid Tumors and Autoimmune Diseases through next-generation CAR-NK and CAR-γδ T cell therapies.





COMPANY NAME	FOUNDERS' NAME
EAST OCYON BIO PRIVATE LIMITED	Dr. Dinesh Kundu & Dr. Renu Kundu

TRL- 4	INTELLECTUAL PROPERTY
Proof of Concept Established In-vivo animal studies Initiated	Indian Patents filed-2 Prov. Patent Appl No.- 202511046315, 202511057336

ABOUT THE TECHNOLOGY

East Ocyon Bio's proprietary allogeneic CAR-NK and CAR-γδ T cell platform offers a curative, off-the-shelf solution for multiple cancers and autoimmune diseases. As compared to conventional CAR-T therapies, it eliminates patient-specific manufacturing, with each dose costing under USD 5,000. Engineered for superior safety and tolerability, it minimizes cytokine release and neurotoxicity while ensuring high efficacy. The technology enables affordable, scalable, and globally accessible next-generation immunotherapies.

USP

- **First-in-class IL2–anti-PD-L1 CAR construct** designed to modulate the tumor microenvironment, enhancing both cytotoxicity and persistence.
- **Dual-action mechanism** combines immune activation with checkpoint blockade for superior tumor clearance.
- **1/5th the cost** of existing CAR-T therapies (e.g., ImmunoACT), ensuring wider accessibility and affordability.
- **Allogeneic, off-the-shelf platform** eliminates patient-specific manufacturing.
- **Excellent safety profile** with no/minimal risk of GvHD, CRS, or neurotoxicity.
- **Scalable in-house manufacturing** using indigenous viral vectors and IL-engineering, supporting global competitiveness and regulatory readiness.

Incubated at BBB I RCB
www.eastocyonbio.com

PROBLEM ADDRESSED

East Ocyon Bio's (EOB) therapy addresses **three** critical challenges in advanced medicine — **lack of effective cures for solid tumors and autoimmune diseases**, **poor management of the immunosuppressive tumor microenvironment, and the prohibitive cost of current CAR-T therapies**. By combining superior immune modulation with affordable, off-the-shelf accessibility, EOB's allogeneic CAR-NK & CAR- GDT cell technology platform delivers a transformative and scalable solution for patients in India as well as globally.

FUNDS RAISED/ACHIEVEMENTS

- Raised $4.2 million (INR 35 crore) in seed funding from Aeravti Ventures I (VC Fund) and Microlabs (Strategic Partner) to support preclinical studies and the establishment of a comprehensive, clinical-grade GMP manufacturing facility.
- Recognized by the Department of Scientific and Industrial Research (DSIR) for its *in-house* R&D unit.
- Established a BSL-2 certified facility for *in-house* generation of viral vectors, strengthening its *end-to-end* cell and gene therapy capabilities.

END USERS/CUSTOMERS

- Government and Private Hospitals
- Cancer and Autoimmune Disease Patients in India and global (Rest of World) markets — enabling access to affordable, next-generation cell therapies
- International Cell & Gene Therapy (CGT) Companies from the US, Europe, China, and Korea seeking to:
  - Partner for local manufacturing and regulatory alignment
  - Utilize East Ocyon Bio's state-of-the-art GMP facility for clinical translation and market entry in India

Med Tech Company

Bleeding Control and Chronic Wound care Products

Application

Anziam Bio delivers innovative, affordable solutions for Bleeding Control and Chronic Wound Care, making advanced healthcare accessible to all

COMPANY NAME	FOUNDERS' NAME
Anziam Bio Private Limited	• **Srayance Jain** • **Sachin Kapoor**
TRL- 9	**INTELLECTUAL PROPERTY**
Commercialized	**Filed**

ABOUT THE TECHNOLOGY

AcuClot is an advanced haemostatic sponge developed to control surgical and superficial bleeding effectively. Powered by ActClot Technology (Activated Clotting Mechanism), its unique composition and structure accelerate the body's natural coagulation cascade, enabling rapid and reliable bleeding control.

USP

- Easy to use
- Quick Action and Rapid Bleeding control
- Charge-based platelet aggregation, enhances blood coagulation
- Biodegradable

END USERS/CUSTOMERS

- Defense
- Security Agencies (BSF/CISF)
- Police
- Rescue teams (NDRF)
- First responder Ambulances (NHAI Ambulances/ Hospital Ambulances)

PROBLEM ADDRESSED

Uncontrolled bleeding due to accidents and trauma remains one of the leading causes of preventable deaths. The lack of easy-to-use and highly effective products for immediate bleeding control is a critical gap, especially in emergency and pre-hospital settings. Acuclot, a chitosan-based haemostatic sponge, provides a simple and rapid solution—requiring no special training and working as easily as placing a cloth on the wound, with instant effect. Its ability to withstand storage at temperatures up to 50°C makes it highly suitable for use in vehicles, remote locations, and extreme environments.

FUNDS RAISED/ACHIEVEMENTS

- Bootstrapped
- Manufacturing License received from DCGI and commercialized

Incubated at BBB I RCB

www.Anziam.com

Immunotherapy

Autologous CAR-T

Application

A Point-of-care CAR-T manufacturing Platform [PoCMAP]



COMPANY NAME

Thrafford Lifescience Pvt. Ltd.

FOUNDERS' NAME

- **Dr. Kadalmani Krishnan**
- **Dr. Anita Chugh**

TRL- 2

INTELLECTUAL PROPERTY

202511022865 – PoCMAP
202511108309 – Allo CART

ABOUT THE TECHNOLOGY

Thrafford Lifescience is developing a Point-of-Care CAR-T manufacturing platform [PoCMAP] to enhance accessibility and scalability in cancer treatment.

- Decentralized manufacturing at hospitals
- Parallel & multi-batch processing that increases upto 40X output
- Platform eliminates freeze/thaw processes
- Compatible with CAR-T, NK, dendritic cell systems

USP

- Higher Accessibility *via* Point-of-Care Manufacturing
- higher Scalability *via* parallel processing and 40X higher throughput

PROBLEM ADDRESSED

Cancer patients face limited access to affordable advanced medical technologies due to challenges related to availability, scalability, and cost-effectiveness.

Since its approval in 2023, less than 1% of eligible patients in India have received CAR-T therapy. Thrafford is determined to bridge this critical demand–supply gap and deliver equitable access to life-saving cell and gene therapies for every patient in need.

FUNDS RAISED/ACHIEVEMENTS

- ₹ 25 L from Start-up India Seed Funds
- $ 150,000 as Grant from GreX, USA

END USERS/CUSTOMERS

Customers : Hospitals, cancer & specialty care

Consumers: Lymphoma & Leukemia patients
Systemic Lupus Erythematosus (SLE)

Incubated at BBB I RCB

WWW.THRAFFORD.COM

Immunotherapy

Advancing Next-Generation CAR-T Cell Therapies

Application

A cell-based immunotherapy platform designed to target and eliminate cancer, with a focus on treating solid tumors



COMPANY NAME
ZoeNCure Therapeutics

FOUNDERS' NAME
Kumar Saurabh, Rahul Katara and Ashutosh Tiwari

TRL- 5
Process Development Initiated

INTELLECTUAL PROPERTY
Prov. Patent appl No. 202511000621

ABOUT THE TECHNOLOGY

ZoeNCure Therapeutics is actively developing CAR-T therapy assets targeting hematological malignancies, including well-established antigens such as CD19, CD70, and BCMA. These therapeutic candidates aim to enhance efficacy, persistence, and safety, addressing key challenges in CAR-T cell therapy. The company is also exploring innovative enhancements to improve CAR constructs, such as metabolic reprogramming, combinatorial targeting, and resistance mitigation strategies.

USP

- Engineered for long-term persistence to overcome the short-lived effects of current CAR-T therapies.
- Utilizes metabolic reprogramming to enhance T cell fitness and resistance to exhaustion.
- Incorporates combinatorial antigen targeting to prevent tumor escape and address heterogeneity.
- Integrates resistance mitigation features to improve efficacy in relapsed or refractory cases.
- Built-in safety and signaling enhancements for greater precision and reduced off-target toxicity.

Incubated at BBB I RCB

www.zoencure.com

PROBLEM ADDRESSED

Current CAR-T therapies often fall short due to limited durability, tumor relapse, and immune escape. Patients frequently experience short-lived responses driven by T cell exhaustion, antigen loss, and resistance. ZoeNCure addresses these challenges by engineering next-generation CAR-T constructs with enhanced persistence, metabolic fitness, and multi-antigen targeting, delivering safer, more durable, and effective therapies for patients with limited treatment options.

FUNDS RAISED/ACHIEVEMENTS

- ZoeNCure has raised ₹3 crore INR in Seed funding, supporting preclinical research, platform optimization, and process development with a signed CDMO partnership.
- An additional ₹10 crore INR commitment from an existing investor will fund R&D expansion, IP development, regulatory prep, and advancement of lead programs candidates.

END USERS/CUSTOMERS

- Cancer patients seeking new hope through CAR-T therapy
- Hospitals adopting advanced cellular immunotherapies
- Oncology centers specializing in CAR-T treatment delivery
- Biopharma partners developing next-generation CAR-T therapies

Zenovocare
TECHNOLOGIES

Med Tech

India's smartest and most effective homecare Tens Device

Application

Provides Instant Pain Relief; Drug-free and non-invasive

Introduces

iThera

India's smartest homecare TENS Device for

Clinical-Grade Instant Pain Relief

COMPANY NAME
Zenovocare Technologies Private Limited

FOUNDERS' NAME
- **Manav Aggarwal**
- **Madhur Mittal**

TRL- 5
Technology Validated

INTELLECTUAL PROPERTY
Patent filing ongoing

ABOUT THE TECHNOLOGY

Transcutaneous Electrical Nerve Stimulation (TENS) is a clinically proven, drug-free therapy that uses low-voltage electrical impulses to relieve pain. These impulses are delivered through electrode pads placed on the skin, stimulating the underlying nerves. TENS blocks pain signals from reaching the brain while simultaneously triggering the release of endorphins—your body's natural painkillers. The stimulation improves blood circulation and reduces muscle tension, offering immediate relief from chronic and acute pain conditions. Because TENS targets the source of discomfort without side effects, it's widely used for back pain, arthritis, nerve injuries, and post-surgical recovery—providing fast, safe, and non-invasive pain relief at home.

USP

Smart TENs Therapy

- Harnesses neuromuscular insight to adapt to your unique needs through a simple, clinically inspired questionnaire that responses are instantly mapped to evidence-based protocols chosen from a library of over 250 different waves
- Waves designed by Physiotherapy Experts with over 70+ years of combined academic and practical Experience
- 65% more effective than traditional devices
- **Custom Electrode Pads**
- First company in India to provide so
- Improves Electrode Pad fit and reduce placement time by 4 times

PROBLEM ADDRESSED

In India, chronic pain is commonly managed with over-the-counter painkillers, often leading to gut issues, ulcers, and long-term organ damage. Access to physiotherapy remains limited, especially in rural and semi-urban areas. Existing TENS devices are often bulky, non-intuitive, and lack personalization, making them unsuitable for home use by elderly or non-tech users. There is a critical need for a smart, portable, and easy-to-use TENS device that provides safe, drug-free pain relief—reducing dependency on painkillers and improving access to effective pain management.

FUNDS RAISED/ACHIEVEMENTS

Received Rs. 85,000 Education Grant by Indian Startup School to put towards upskilling founders

END USERS/CUSTOMERS

- Urban Working Professionals (30-55 years)
- Looking for a personal hands-on, drug-free, compact, and on the go, discreet Pain relief solution to use in urban settings
- Elderly Individuals (55+ years)
- Looking for simple, wireless (hassle-free), affordable, remote controlled products

Incubated at BBB I RCB

https://www.linkedin.com/company/zenovocare-technologies/

In Vitro Diagnostics

High quality diagnostic products

Application

RT PCR based Diagnostics for Typhoid

COMPANY NAME	FOUNDERS' NAME
Vanguard Diagnostics Pvt. Ltd.	Veena Kohli
TRL- 9	**INTELLECTUAL PROPERTY**
Products Commercialized	Patent No. 355208

ABOUT THE TECHNOLOGY

VANSCAN Typhoid RT PCR Test is a molecular diagnostic test for the qualitative detection of Salmonella Typhi and Salmonella Paratyphi in human blood. This works on the principle of nucleic acid amplification through Real Time Polymerase Chain Reaction (RT PCR), with the help of a specific set of primers targeting a signature DNA and its detection by a specific probe. When the probe is intact, the proximity of the reporter dye to the quencher dye results in suppression of the reporter fluorescence. When probe hybridizes with one of the amplified fragment, the fluorophore is separated from the quencher resulting in the emission of fluorescence. The fluorescent signal is measured in each cycle of the reaction, and the threshold cycle value is determined from the obtained curve.

USP

- Detects Salmonella Typhi and *Salmonella Paratyphi* directly from whole blood using PCR.
- Utilizes a unique primer and probe sequence that is highly specific and conserved.
- Eliminates the need for culture incubation, saving critical time.
- Provides same-day results for faster diagnosis and treatment decisions.

PROBLEM ADDRESSED

VANSCAN Typhoid RT PCR Test will ensure the definitive and early detection (same day reporting) of Typhoid fever thus facilitating the administration of the right antibiotics for treatment. This will contribute significantly towards slowing down the threat from Antimicrobial Resistance (AMR) in India.

FUNDS RAISED/ACHIEVEMENTS

- VANSCAN Typhoid RT PCR Test not only in Indian market, but also we are exporting.
- No funding acquired for this, totally bootstrapped.

END USERS/CUSTOMERS

- Diagnostic Labs
- Primary health centers
- International Market

Incubated at BBB I RCB

https://www.vanguarddiagnostics.com

In Vitro Diagnostics

High quality diagnostic products

Application

RT PCR based Diagnostics for Sickle Cell Disease

COMPANY NAME	FOUNDERS' NAME
Vanguard Diagnostics Pvt. Ltd.	Veena Kohli
TRL- 9	**INTELLECTUAL PROPERTY**
Products Commercialized	Patent No. 355208

ABOUT THE TECHNOLOGY

VANSCAN SCD RT-PCR Kit is a nucleic acid based real time polymerase chain reaction (RT PCR) test for qualitative screening of a point mutation associated with Sickle Cell Disease (SCD) in genomic DNA isolated from whole blood of individuals suspected of SCD.

This works on the principle of nucleic acid amplification through Real Time Polymerase Chain Reaction (RT PCR), with the help of a specific set of primers targeting a signature DNA and its detection by a specific probe. When the probe is intact, the proximity of the reporter dye to the quencher dye results in suppression of the reporter fluorescence. When probe hybridizes with one of the amplified fragment, the fluorophore is separated from the quencher resulting in the emission of fluorescence.

The fluorescent signal is measured in each cycle of the reaction, and the threshold cycle value is determined from the obtained curve.

USP

- Whole Blood PCR.
- Unique primer and probe sequence is highly specific to identify and differentiate carrier and diseased samples of patient.

PROBLEM ADDRESSED

SCD leads to chronic anemia, acute painful episodes, organ infarction and chronic organ damage and by a significant reduction in life expectancy. The Government of India has launched a mission to eliminate sickle cell anemia by 2047.

The mission entails focus on awareness creation, and universal screening of approximately seven crore people in the 0-40 years age group in affected tribal areas. This kit will help in addressing this mission of India.

FUNDS RAISED/ACHIEVEMENTS

- No funding acquired for this, totally bootstrapped.
- VANSCAN SCD RT PCR Test Kit was validated and approved by ICMR.
- Data submitted to CDSCO for the grant of manufacturing license.

END USERS/CUSTOMERS

- Diagnostic Labs
- Primary health centers
- International Market

Incubated at BBB I RCB

https://www.vanguarddiagnostics.com

In Vitro Diagnostics

High quality diagnostic products

Application

POCT based Diagnostics for Sickle Cell Disease

COMPANY NAME	FOUNDERS' NAME
Vanguard Diagnostics Pvt. Ltd.	Veena Kohli
TRL- 9	**INTELLECTUAL PROPERTY**
Products Commercialized	Patent No. 355208

ABOUT THE TECHNOLOGY

VANSCAN SCD POCT Test is a point of care test with dried blood spot (DBS) sample. In this method

- DNA is extracted from DBS
- Then DNA is isothermally amplified.
- Then this amplified products are made to run on LFA Card

On LFA card, there will be 3 markers as :

- C:Controlline
- W:Wild
- M:Mutant

If Line appears is on C, M and W sample is Carrier.
If Line appears is on C & M, sample is SCD.
If Line appears is on C & W, sample is Normal.



USP

It's a point of care technique and involve simple isothermal method along with lateral flow assay to identify single point mutation in sickle cell diagnosis.

PROBLEM ADDRESSED

SCD leads to chronic anemia, acute painful episodes, organ infarction and chronic organ damage and by a significant reduction in life expectancy. The Government of India has launched a mission to eliminate sickle cell anemia by 2047.

The mission entails focus on awareness creation, and universal screening of approximately seven crore people in the 0-40 years age group in affected tribal areas. This kit will help in addressing this mission of India.

FUNDS RAISED/ACHIEVEMENTS

- No funding acquired for this, totally bootstrapped.
- This method of point mutation detection will be first of its kind in clinical diagnosis of patients at POCT level.

END USERS/CUSTOMERS

- Diagnostic Labs
- Primary health centers
- International Market

Incubated at BBB I RCB

https://www.vanguarddiagnostics.com

Biotechnology

TechInvention Lifecare Ltd. is committed to developing essential vaccines, diagnostics, and biotherapeutics to ensure global health equity and access in the developing world.

Application

A 16-valent pneumococcal conjugate vaccine candidate for the prevention of invasive pneumococcal disease caused by 16 clinically relevant *S. pneumoniae* serotypes.

COMPANY NAME	FOUNDERS' NAME
TechInvention Lifecare Ltd.	**Mr. Syed S Ahmed**
TRL-5	**INTELLECTUAL PROPERTY**
Efficacy and Safety studies completed	**IN202121017114**

ABOUT THE TECHNOLOGY

TechInvention Lifecare Ltd. is developing PneumoWin®, a 16-valent pneumococcal conjugate vaccine designed to protect against invasive pneumococcal disease caused by 16 clinically significant serotypes. The vaccine includes 13 serotypes present in Prevenar 13 and adds 12F, 15A, and 22F -emerging serotypes linked to antimicrobial resistance and increased disease burden in LMICs. PCV-16 uses recombinant CRM197 as the carrier protein and is produced on a platform enabling cost-effective manufacturing. Currently advancing through immunogenicity evaluations, the vaccine is tailored for LMIC settings, offering broad-spectrum, affordable, and scalable protection with the potential for inclusion in national immunization programs and global procurement channels

USP

- Broad coverage with 16 serotypes, including emerging strains (12F, 15A, 22F)
- Addresses antimicrobial resistance by reducing infection incidence
- Designed for affordability and scalability in LMIC settings
- Uses proven recombinant CRM197 carrier for enhanced efficacy
- Aligned with WHO and NIP integration pathways
- Competitive alternative to PCV13/14 with tiered pricing model

PROBLEM ADDRESSED

Pneumococcal disease causes significant morbidity and mortality, especially in children under five and adults over 65, with developing countries bearing the highest burden. Despite existing vaccines, gaps remain in serotype coverage—particularly against emerging strains like 12F, 15A, and 22F. Rising antimicrobial resistance further complicates treatment, making prevention through vaccination the most viable solution. India alone accounts for a quarter of global childhood pneumonia cases. TechInvention's PCV-16 addresses the limitations of current PCVs by expanding serotype coverage, reducing AMR risks, and offering a cost-effective solution suitable for LMICs where high disease burden and limited vaccine access persist.

FUNDS RAISED/ACHIEVEMENTS

- ISO 9001:2015 and ISO 13485:2016 certification
- Listed by Forbes India in top 200 companies with Global Business Potential
- Fortune Leadership award for Excellence in Bio-innovation in 2024
- 2021 SME Excellence awardee in healthcare by SME Chamber of India
- Listed amongst top 100 innovate SME's of 2021 by Innovation Council, Geneva
- 30+ Research abstract acceptances in global conferences of repute

END USERS/CUSTOMERS

- National immunization programs in LMICs supported by WHO and UNICEF
- Gavi-supported and non-Gavi middle-income countries
- Children under 5 and adults over 65
- Individuals with chronic illnesses or immunosuppression
- Private pediatric and adult immunization providers

Incubated at BBB I RCB
https://techinvention.biz/

Bio - Pharma

TechInvention Lifecare Ltd. is committed to developing essential vaccines, diagnostics, and biotherapeutics to ensure global health equity and access in the developing world.

Application

A recombinant hexavalent vaccine candidate for the prevention of invasive meningococcal disease caused by serogroups A, B, C, W, X, and Y.

COMPANY NAME
TechInvention Lifecare Ltd

FOUNDERS' NAME
Mr. Syed S Ahmed

TRL-4
Proof-of-concept animal studies completed

INTELLECTUAL PROPERTY
IN202421033292

ABOUT THE TECHNOLOGY

TechInvention Lifecare Ltd. is developing MenHexa®, a recombinant 6-in-1 vaccine targeting all six major Neisseria meningitidis serogroups: A, B, C, W, X, and Y. It combines polysaccharide conjugates (A, C, Y, W, X) with recombinant factor H-binding protein (fHbp) from serogroup B. Designed for cost-effective production using E. coli expression systems, MenHexa® aims to meet WHO prequalification standards. The platform offers broad-spectrum protection and is tailored for LMICs, where disease burden is high. Proof-of-concept studies show strong immunogenicity for MenHexa, with the full formulation advancing through preclinical development.

USP

- First-of-its-kind recombinant hexavalent MenA–B–C–W–X–Y vaccine
- Broad protection against all six WHO-priority Neisseria meningitidis serogroups
- Affordable and scalable production using E. coli-based expression and purification system.
- Designed for WHO prequalification to enable access via global procurement agencies
- Potential to replace multiple separate meningococcal vaccines with one affordable combination.

PROBLEM ADDRESSED

Current combination meningococcal vaccines like Penbraya® (Pfizer) and Penmenvy® (GSK) are approved in high-income countries but remain unaffordable for low- and middle-income countries (LMICs), where disease burden is highest. These vaccines also exclude serogroup X, a growing threat in sub-Saharan Africa. No licensed vaccine currently covers all six WHO-priority serogroups: A, B, C, W, X, and Y. TechInvention's MenHexa® addresses this gap as a recombinant, affordable 6-in-1 vaccine designed for LMICs. Using scalable E. coli-based technology, MenHexa® enables cost-effective production and aims to support national immunization programs and global procurement through WHO, Gavi, and UNICEF.

FUNDS RAISED/ACHIEVEMENTS

- Awarded a BACTIVAC grant to support functional immunogenicity studies conducted in collaboration with UKHSA
- ISO 9001:2015 and ISO 13485:2016 certification
- Listed by Forbes India in top 200 companies with Global Business Potential
- Fortune Leadership award for Excellence in Bio-innovation in 2024
- 30+ Research abstract acceptances in global conferences of repute

END USERS/CUSTOMERS

- Global agencies (WHO, Gavi, UNICEF) for mass immunization
- Private sector for travelers, immunocompromised, and military
- LMIC government programs in high-burden regions
- High-risk groups: infants, teens, immunocompromised, outbreak zones

Incubated at BBB I RCB
https://techinvention.biz/

VeGen Labs
Redefining Drug Discovery
Molecule to Medicine

Small Molecule Therapeutics

A precision oncology company addressing the high unmet need of cancer patients

Application

Therapeutic Indication : Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Tripple Negative Breast Cancer (TNBC), Recurrent Ovarian Cancer (OCRA) and Prostate Cancer

COMPANY NAME
VeGen Labs LLP

FOUNDERS'
Prashant Bhavar
Uday Kumar S

PRODUCTS

TLR - 4

INTELLECTUAL PROPERTY
4 PCT Filed
2 National Phase Entry

IND126
KRASG12
Inhibitor
NSCLC& CRC

VRTX531
USP1
Inhibitor
TNBC & OCAR

ABOUT THE TECHNOLOGY

Leveraging advanced platforms and cutting-edge technology including AI to drive small molecule innovation, addressing critical unmet needs in the treatment of solid tumours.

PIPELINE		
IND126	*TLR-4*	*Ready for IND Tox*
VRTX531	*TLR-4*	*Ready for IND Tox*
Pan-KRAS	*TLR-2*	*Lead Optimisation*

USP	
KRASG12Ci "IND126	*USP1i "IND531*
Global Market: 4.0 bln US$, 2029	*Global Market: 1.6 bln US$, 2033*
Next-Gen KRAS G12 inhibitor with enhanced efficacy and optimized pharmacokinetics, designed to overcome resistance	*First-in-Class target with superior efficacy and the potential to reduce toxicities, intolerance, and resistance observed with standard of care.*
Go to Market: 2028	*Go to Market – 2029*
Patent Term: 2042	*Patent Term: 2044*

PROBLEM ADDRESSED

High Unmet Need in Solid Cancers	
Lung (NSCLC)	***13 % pts** KRASG12C*
Colorectal (CRC)	***4 % pts** KRASG12C*
Ovarian	***30-40% pts** Relapse, Refractory, Ineligible or Progress on Standard of Care*
Breast (TNBC)	
CR-Prostate	

FUNDS RAISED/ACHIEVEMENTS

- Raised INR 12+ Cr from Angels & Bootstrap
- Two Leads at TLR 4 (Ready for IND Tox)
- BIG Grant – INR 50 Lakh
- BIRAC–SBIRI Grant –INR 3.76 Cr
- 4 PCT Patent Applications filed
- National Patent filing in 100 + Countries
- Patent Granted in Eurasian Region

END USERS/CUSTOMERS

- Global Biotech (US, CN &, KR JP)
- Big Pharma Giants
- Indian Pharma
- Cancer Patients (Commercialization in INDIA)

Incubated at BBB I RCB
www.vegen.in

Digital Healthcare

"HeaLink: A Digital-First, Portable Healthcare Ecosystem for Schools and Students"

Application

Smart health cards that provide instant access to student health records, support on-campus healthcare, and connect to medical services anytime, anywhere.

COMPANY NAME
THIRD AI PLATFORMS PVT. LTD. (HeaLink)

FOUNDERS' NAME
ABIR SATSANGEE

TRL- 9

INTELLECTUAL PROPERTY
Filed

ABOUT THE TECHNOLOGY

HeaLink is built on ABHA-compliant architecture, enabling secure and interoperable exchange of health data with portability across providers. It leverages NFC-enabled smart health cards and facial recognition for instant and reliable student identification, even in offline settings. A cloud-based infrastructure supports real-time record access and updates, while advanced encryption safeguards sensitive information. Designed for scalability, the platform integrates seamlessly with telemedicine, diagnostics, and wearable devices, creating a connected ecosystem that provides schools, parents, and healthcare providers with accurate and accessible student health information.

USP

- ABHA-Compliant & Portable – Ensures secure, nationwide portability of student health records across providers and locations.
- Instant Access – NFC-enabled smart cards and facial recognition enable quick and reliable identification, even without internet.
- School-Integrated – Designed to seamlessly align with school health programs, covering preventive, mental, and emergency care.
- Secure & Private – Offers end-to-end encryption with strict compliance to data privacy standards.
- Multi-Service Connectivity – Integrates with telemedicine, diagnostics, and other healthcare services to deliver comprehensive care access.
- Offline Capability – Functions effectively in low-connectivity areas, ensuring uninterrupted access to health records.

PROBLEM ADDRESSED

In India, student health records are largely fragmented, paper-based, and often unavailable when needed. This leads to delayed care, repeated tests, and ineffective health monitoring. Schools lack structured systems to manage preventive health, mental wellbeing, and emergency response, while parents face challenges in accessing a child's complete medical history across multiple providers. As a result, early detection of health issues is frequently missed, coordination between schools, parents, and healthcare professionals remains inefficient, and continuity of care is disrupted when students move between schools or cities. HeaLink bridges this gap by providing a secure, portable, and school-integrated health management platform that makes every child's health data accurate, accessible, and actionable.

FUNDS RAISED/ACHIEVEMENTS

- Government & Industry Recognition – Selected under SAMRIDH 2.0 by MeitY and chosen for the Moopen's KLAP Innovation Program.
- Regulatory Approval – Licensed by the Ayushman Bharat Digital Mission (ABDM) for secure health data exchange.
- Institutional Backing – Supported by leading organizations including Indian School of Business – Hyderabad (I-Venture), Wadhwani Foundation, NVIDIA Inception Programme, Shiv Nadar University AIC, and the Regional Centre for Biotechnology.

END USERS/CUSTOMERS

- Schools & Educational Institutions – To manage preventive health, mental wellbeing, and emergency care for students.
- Parents & Guardians – To access a child's complete, portable, and secure medical history across providers and locations.
- Healthcare Providers – To enable seamless, interoperable access to student health records for accurate diagnosis and continuity of care.
- Government & Public Health Agencies – To strengthen school health programs, early detection, and population health monitoring.

Incubated at BBB I RCB
www.healport.in

Vaccine & Biologicals

Developing technologies for Novel cell culture based vaccine with improved thermostability

Application

Vaccine platforms technology for fast and efficient vaccine development for emerging or re-emerging diseases.

COMPANY NAME

Vaxfarm Life Sciences Pvt Ltd.

FOUNDERS' NAME

Dr. Anurag Gupta

TEST VACCINE VIALS

COMBINED SP, GP & PPR VACCINE

CHIKUNGUNYA VACCINE

HEPATITIS E VACCINE

ABOUT THE COMPANY & TECHNOLOGY

VaxFarm Life Sciences a Start-up biotech company focused on Innovation and Research in areas of Vaccines and Biologicals. It is currently working in developing vaccines and bio therapeutics on diseases areas with major unmet needs in both in Animal and Human healthcare. It has a good portfolio of vaccine under development some of them are supported by Government. The Company's key strength is embedded in its cutting-edge research and development capabilities. Company is also capable of developing vaccine platforms that allow fast and efficient vaccine development for emerging or re-emerging diseases. The technology developed by us is a Novel cell culture based vaccine with improved thermostability.

INTELLECTUAL PROPERTY

- An Inactivated Liquid Combination Vaccine for Sheep Pox, Goat Pox & PPR Disease with Improved Thermostability – **Patent Granted**
- A Live Attenuated Cell Based combined Vaccine for Sheep Pox, Goat Pox & PPR Disease with Improved Thermostability – **Patent Granted**
- An Inactivated Vaccine for Chikungunya Virus Infection – **Patent under Prosecution**
- A Live Attenuated Cell-Based Vaccine for Chikungunya Virus Infection– **Patent under Prosecution**

FUNDS RAISED/ACHIEVEMENTS

- DBT/BIRAC-BIG
- DBT BIRAC-NBM

END USERS/CUSTOMERS

- Sheep Pox, Goat Pox & PPR Vaccines: Livestock farmers, veterinarians, and government animal health departments.
- Chikungunya Vaccines: Hospitals, healthcare providers, public health agencies, and pharmaceutical companies.

Incubated at BBB I RCB

www.VAXFARM.COM

Diagnostics

Stellar Diagnostics India Pvt. Ltd has developed the first low-cost, simple and rapid Point-of-care (POC) test that is independent of sputum, for detection of active TB in the lateral flow format.

Application

The POC TB test uses blood from a finger-prick as a sample and is simple enough to be used by health-care workers in peripheral settings, in private clinician clinics and in screening of communities at high-risk for TB, such as house-hold contacts of infectious TB patients, residents of slums, HIV-infected individuals, patients with other lung diseases etc.

COMPANY NAME
STELLAR DIAGNOSTICS INDIA PRIVATE LIMITED

FOUNDERS' NAME
Mr. ARVIND WALIA, MD
Dr. SUMAN LAAL, CSO

TRL- 8

INTELLECTUAL PROPERTY
Peptides Patented

ABOUT THE TECHNOLOGY

The Stellar POC rapid Triage test is based on lateral flow technology and detects circulating antibodies directed against peptides derived from highly immunogenic ***M.tuberculosis*** **specific cell-wall** proteins. These peptides were originally identified in the labs of Dr. Laal during her research at NYU and are patented by NYU and licensed to Stellar.
10ul blood obtained by finger-prick is added to the sample port of the lateral flow device, followed by three drops of a buffer. The results are read visually 10-15 mins post addition of the blood and buffer; a mobile app that interprets the results.

USP

- First Sputum Independent test
- Rapid, cost effective, easy to operate, requires minimal personnel training
- No need for laboratory instruments or infrastructure.

PROBLEM ADDRESSED

India bears almost a quarter of the global TB burden, with an estimated 2.5 million new cases of active TB annually. Only one in 7-10 individuals with clinical symptoms that lead to suspicion of TB actually has TB. The currently available diagnostic tests for TB (bacterial culture, CB NAATs) cannot be used to screen every TB suspect due to the cost, infrastructure and training requirements. Stellar POC rapid triage test can narrow down the numbers of TB suspects who need to be referred for confirmatory testing (Bacterial culture, NAATs).

FUNDS RAISED/ACHIEVEMENTS

- USAID/BIRAC
- BIRAC
- India health Fund
- Strategic tie up with Molbio for commercialization

END USERS/CUSTOMERS

Healthcare workers in Hospitals or Primary healthcare centers.
Clinicians in Private clinics.

Incubated at BBB I RCB
https://www.stellardiagnostics.in/

Bio - Pharma

Cell Derived Embryo (CDE): Development of bovine-induced blastocyst (biBL) from bESCs

Application

Embryos derived using stem cells would be available to the farmers at relatively very low prices

COMPANY NAME
Tropical Animal Genetics Pvt. Ltd.

FOUNDERS' NAME
Dr. Pravin Kini

TRL- 6

INTELLECTUAL PROPERTY
To be applied



IVF EMBRYO ESC DERIVED EMBRYO

ABOUT THE TECHNOLOGY

The technology involves development of an in vitro method to produce bovine embryos using bovine embryonic stem cells. The method involves use of growth factors to reprogram ESCs to blastocysts without any genetic modifications using viral vectors. Use of ESCs to make blastocyst in various species has been attempted (mouse, human, goat, pig, monkey, & bovines). However, no ready to adapt protocols are available with commercial potential

USP

- Stem cell derived embryo is going to be far cheaper than IVF derived embryos
- This will increase their availability and affordability to the marginal farmer
- The technology will serve as a new intervention for genetic gain in live stock breeds

PROBLEM ADDRESSED

- Technology will help to produce high fidelity female embryos at an affordable price
- Will replace or limit the requirement of IVF & SCTNT derived bovine embryos for embryo transfers
- Open avenues to develop methods for genetically modifying bovines for desired traits
- Fast genetic propagation through E-to-E breeding

FUNDS RAISED/ACHIEVEMENTS

- 600K USD from BMGF

END USERS/CUSTOMERS

- Dairy Cooperatives & Federations
- Progressive Commercial Dairy Farms
- Government Breeding Programs
- Elite Breeding Centers & Elite Farmers

Incubated at BBB I RCB
https://taggnx.com/

Psaizi
Transforming Neurocare Together, Anywhere

Deep Tech Seizure Forecasting

Application

- Automated flagging of seizure events
- Prediction of a seizure event in real-time

COMPANY NAME
Psaizi Technologies Pvt. Ltd.

FOUNDERS' NAME
- **Dr. Suman Das**
- **Dr. Rajat Anand**
- **Deepti Mathur**

TRL- 7

INTELLECTUAL PROPERTY
NA



ABOUT THE TECHNOLOGY

SeiziSense integrates with existing EEG devices/ in-house portable EEG device to deliver actionable insights, reducing risks and optimizing treatment

improves preparedness for caregivers and augments decision-making for clinicians

PROBLEM ADDRESSED

Problem	Benefit to Doctors	Benefit to Patients	Benefit Caregivers
Missed seizures between visits	Objective seizure logs	Better seizure tracking	Confidence in care
Unpredictable seizure occurrence	Enables preventive care	Improves autonomy	Peace of mind
Drug response monitoring	Data-driven dosing	Faster relief	Avoids distress
Misdiagnosis or unclear seizure type	Identifies non-compilance	Helps build routines	Easler to supervise meds
Seizure-ralated injury or SUDEP	Improves diagnostic accuracy	Reduces emotional strain	Can respond early

SeiziSense

FUNDS RAISED/ACHIEVEMENTS

- 50 lakh from BIRAC

END USERS/CUSTOMERS

- Hospitals
- Diagnostic Labs
- Clinicians
- Epileptic Patients
- Caregivers

Incubated at BBB I RCB
www.psaizi.com

Food Safety and Diagnostics

Indigenous Development and Commercialization of Certified Aflatoxin Standards and Integrated Diagnostic Tools for Food Safety



Application

The project's output, including certified AFB1 reference materials and advanced diagnostic kits, will enable precise aflatoxin quantification and rapid, on-site detection, crucial for enhancing food and feed safety, public health, and trade in India.

COMPANY NAME	FOUNDERS' NAME
Proteogenixx Lifescience Pvt. Ltd.	**Ms. Pooja D. Shah**
TRL- 2	**INTELLECTUAL PROPERTY**
(Technology Concept Formulated)	**To be filed**

ABOUT THE TECHNOLOGY

The project on aflatoxin standards and diagnostic kits integrates a suite of advanced technologies to address critical food safety challenges.

For the **aflatoxin standard production**, the technology involves fermentation processes for high-yield fungal growth, followed by multi-step chromatographic purification techniques. This purified material then undergoes rigorous characterization to ensure its identity, purity, and traceability as a Certified Reference Material.

Concurrently, the development of **diagnostic kits** leverages diverse, cutting-edge platforms: **RT-PCR kits** employ molecular biology techniques; **ELISA kits** utilize advanced immunoassay principles and **antibody-based Lateral Flow Assays (LFA)** provide rapid, user-friendly, and cost-effective on-site screening by employing immunochromatographic principles.

USP

- **Indigenous Metrological Certification:** First-ever national certification of Aflatoxin CRM by CSIR-NPL in India.
- **Multi-Platform Diagnostic Suite:** Offers RT-PCR, ELISA, and LFA, providing comprehensive detection options.
- **Tailored for Indian Matrices:** Kits and methodologies optimized for diverse Indian food/feed.
- **Strong Academia-Industry Synergy**: Unique collaboration driving research to commercialization.
- **Reduced Import Reliance**: Directly supports "Make in India" for critical food safety tools.

Incubated at BBB I RCB

https://proteogenixx.com/

PROBLEM ADDRESSED

Aflatoxin contamination in food and feed poses a pervasive and severe threat to public health, food security, and agricultural economies, particularly in warm, humid climates like India.

The current reliance on imported Certified Reference Materials (CRMs) and diagnostic kits creates significant financial burdens, logistical challenges, hindering accurate and consistent quantification of the toxin. This results in inadequate surveillance, delayed detection of contaminated products, substantial economic losses due to rejected exports and unsafe domestic consumption, and a persistent public health risk from chronic aflatoxin exposure, particularly liver cancer and childhood stunting.

FUNDS RAISED/ACHIEVEMENTS

- Recently applied for DBT BIRAC Joint Call for Proposals on मूलांकुर Bioenablers: Biofoundries and Biomanufacturing hubs under BioE3 Policy in collaboration with CSIR-NPL, IARI-Division of Plant Pathology and University of Mysore

END USERS/CUSTOMERS

- Food Testing Laboratories (Government & Private)
- Food Processing Units & Manufacturers
- Agricultural Sector (Farmers, Farmer Producer Organizations - FPOs, Traders, Exporters)
- Regulatory Bodies & Government Agencies (e.g., FSSAI, BIS, Agricultural Departments)
- Research Institutions & Universities

Industrial Biotechnology

Next-Generation Plant-Based Protein and Probiotics Fish Feed for Aquariums and Urban Hobbyists

Application

Vegan Fish Feed for Aquariums and Urban Fish Enthusiasts.

COMPANY NAME
Translational Research & Innovation Pvt Ltd

FOUNDERS' NAME
Dr. Alok Adholeya

TRL- 8
(Revenue generation stage)

INTELLECTUAL PROPERTY
Indian Patent Application No.: 202311045686

ABOUT THE TECHNOLOGY

Bio Guru 3F Pro is a pioneering, eco-friendly fish feed that is entirely plant-based and packed with probiotics. It is India's first vegan, bio-fermented fish feed made without fishmeal, fish oil, or any animal-derived ingredients. Unlike conventional feeds containing artificial additives and animal residues, 3F Pro uses natural, clean ingredients combined with beneficial probiotics and herbal nutrients to promote fish health and growth.

Key Benefits:

- 100% plant-based, animal-free protein source
- Enhances nutrient absorption, digestion, and immune response
- Lowers waste, improving water quality in aquariums and ponds
- Supports faster growth and reduces fish mortality

This innovative feed tackles environmental concerns linked to traditional fish feeds, which can harm water ecosystems. Designed to be scalable and environmentally friendly, Bio Guru 3F Pro is suitable for high-performance fishkeeping and aquaculture worldwide.

USP

A complete, cost-effective solution that boosts fish health, vibrancy, and energy—all while reducing management efforts. Ideal for both freshwater and marine fish, it promotes sustainable and profitable fish rearing.

Incubated at BBB I RCB
https://triindia.org/

PROBLEM ADDRESSED

Conventional fish feeds depend heavily on fishmeal—using up to 20 million tonnes of wild fish annually (FAO 2014)—and often face issues like microbial contamination. Processing can also destroy beneficial probiotics, limiting gut health benefits for fish.
Our patent-pending probiotic-encapsulated floating feed overcomes these problems by using plant proteins and locally sourced probiotics. This approach:

- Improves gut health and immunity
- Reduces reliance on antibiotics
- Provides an eco-friendly, affordable alternative

What Makes Us Different:
Our nutritious, probiotic-rich feed is eco-conscious, enhances fish resilience, and supports market competitiveness. Bio Guru 3F Pro is a plant-based, sustainable fish feed that lowers costs, speeds up growth, and increases disease resistance—perfect for hobbyists and ornamental fish keepers worldwide

FUNDS RAISED/ACHIEVEMENTS

- Secured a ₹20 lakh loan from the Startup India Seed Fund Scheme
- Featured at the People's Festival of Innovations, New Delhi
- Launched the world's first vegan fish feed at Global Bio India 2023
-

END USERS/CUSTOMERS

- Urban hobby fish enthusiasts
- Professional aquariums worldwide

Diagnostics

We are developing a rapid, affordable, and non-invasive diagnostic test for early detection of prenatal chromosomal abnormalities using biomarker based technology

Application

To enable non-invasive, early diagnosis of chromosomal abnormalities during prenatal pregnancy.

COMPANY NAME

PrecizionIQ Data Pvt Ltd

FOUNDERS' NAME

- Dr. Murli Manohar (CEO)
- Dr. Pedro Rodrigues (CTO)
- Dr. Kamal Tyagi (CSO)
- Mr. Anurag Dikshit (CGO)
- Mr. Amit Kumar (COO)

TRL- 3

INTELLECTUAL PROPERTY

Patent filed

ABOUT THE TECHNOLOGY

We are developing a next-generation diagnostic test that functions similarly to a pregnancy test. However, instead of detecting pregnancy, it identifies prenatal chromosomal abnormalities at a very early stage.

The test detects biomarkers that are specifically altered in the mother's blood or urine samples in response to fetal chromosomal abnormalities. A defined panel of these biomarkers would serve as a highly accurate signature for specific syndromes.

Using advanced metabolomics, we analyze thousands of metabolites in biological samples to discover molecular patterns associated with targeted chromosomal conditions

USP

- Early, Non-Invasive Detection: Prenatal chromosomal abnormalities can be detected earlier in pregnancy without invasive procedures.
- Increased Accuracy & Reliability: The enhanced sensitivity reduces the likelihood of false positives and unnecessary stress for expecting parents.
- Accessible & Affordable Testing: Scalable and cost-effective diagnostics to make early prenatal testing available to a broader population.

Incubated at BBB I RCB
https://triindia.org/

PROBLEM ADDRESSED

Pregnancy is a time of hope, yet nearly 1 in 5 pregnancies ends in miscarriage. Many of these losses are linked to underlying biological conditions like chromosomal aberrations, which are often misdiagnosed until it's too late. In India, with over 25 million pregnancies annually, many families face preventable losses or the birth of children with detectable conditions due to unreliable screening methods and confirmatory tests come too late in the pregnancy to have meaningful outcomes. Despite advances in prenatal care, there is an urgent need for early diagnostic solutions that are accurate, affordable, and accessible to all, ensure no family endures prolonged fear, anxiety and uncertainty.

FUNDS RAISED/ACHIEVEMENTS

- Raised $250,000 in pre-seed funding from a US based angel investor

END USERS/CUSTOMERS

- Primary end users: Pregnant women and expectant
- couples seeking early, non-invasive solutions.
- Secondary end users: Private hospitals, diagnostic laboratories, and MedTech companies involved in the development, distribution, and adoption of prenatal tests.
- Strategic partners: Insurance companies and government health schemes to help subsidize the test cost and enhance accessibility.

Medical Device

Kriash is innovating maternal and child healthcare through device NeoSense that improves neonatal outcomes, enhances Kangaroo Mother Care (KMC) adoption, and drives economic impact by reducing NICU stays and healthcare costs.

Application

Kriash's non-invasive device 'NeoSense' lies at the intersection of wireless real-time vitals monitoring and Skin-to-skin Contact (SSC) duration tracking to enhance and scale Kangaroo Mother Care (KMC).



COMPANY NAME	FOUNDERS' NAME
Kriash Medtech Pvt. Ltd.	**Dr. Neetika Ashwani**
TRL- 4	**INTELLECTUAL PROPERTY**
Technology Validated in Lab	**Filed Provisional Patent**

ABOUT THE TECHNOLOGY

NeoSense integrates IoT-enabled sensors to monitor key neonatal vitals—temperature, heart rate, SpO_2, respiratory rate—and accurately track SSC duration. Unlike traditional NICU setups that rely on cumbersome wired monitors, NeoSense enables mobility, comfort, and zero-separation during KMC. device syncs with a mobile application and the cloud backend, providing data analytics, alerts, and reports to caregivers and healthcare providers. AI-driven algorithms ensure accuracy even in dynamic clinical environments, making it scalable for both hospital and home/community-based settings.

USP

- Tracks KMC + Vitals in real time – first of its kind
- Wireless & Non-invasive – no discomfort, no wires
- AI-powered alerts – detects early complications
- Plug & play – no extra training needed
- Affordable & scalable – fits both urban and rural NICUs
- Backed by patents & global programs – trusted innovation

Incubated at BBB I RCB

www.kriash.org

PROBLEM ADDRESSED

The practice of Kangaroo Mother Care (KMC) in NICUs and SNCUs remains critically low, primarily due to **cumbersome, wired monitoring systems** and the **lack of automated tools** to track skin-to-skin contact duration and newborn vitals. This results in **missed clinical complications**, **weakened maternal-infant bonding**, and **reduced adoption of KMC**, despite its proven ability to reduce neonatal mortality by up to 40%. The absence of real-time data and user-friendly monitoring tools also contributes to **higher rates of postpartum depression (PPD)** and **increased healthcare costs** due to prolonged NICU stays—especially in under-resourced settings.

FUNDS RAISED/ACHIEVEMENTS

- **₹10 Lakhs** grant under **NIDHI PRAYAS** (DST, Govt. of India)
- **Provisional patents** filed in India & USA
- **Incubated at Columbia Startup Lab**, New York
- Selected for **multiple global accelerators**: WE HUB, TiE Women, Project 2.8, Catalyst (Westchester), RICH, Wadhwani Foundation
- **Clinical feasibility demonstrated** on 5 preterm babies
- **100% woman-led team** with expertise in medtech, AI, public health, and pediatrics

END USERS/CUSTOMERS

- Neonatologists/ Pediatricians
- NICU/SNCU Nurses/ Hospital Administrators
- Mothers & Families of Preterm Babies
- Public & Private Hospitals
- Government Health Agencies
- NGOs & Nonprofits in Maternal-Child Health
- Global Health Organizations & Donors

Micronic
Smart Medical Devices

In Vitro Diagnostics

Development & Production of Recombinant Antigen and Monoclonal Antibodies for In-Vitro Diagnostic Kits including Rapid Test and ELISA

Application

To enable rapid, reliable, and high-performing immunoassays by providing validated raw materials,.

COMPANY NAME
Micronic Analytical Devices Pvt.Ltd.

FOUNDERS' NAME
Jatin Agrawal/ Dr Anurag Gupta

ABOUT THE COMPANY & TECHNOLOGY

Established in 2021, Micronic was founded with a clear purpose: to become the backbone of India's in vitro diagnostics (IVD) industry.

Led by a strong team of veteran biotechnologists and experienced immunoassay developers, we have built the capability to develop, validate, and manufacture critical antigens, antibodies, and enzymes used in ELISA and lateral flow immunoassays.

Micronic is a deep-tech enterprise for IVD bio-reagents. Our team manages every step of the product journey – from sequence selection and protein expression to stringent assay validation for batch release, combining scientific depth with operational agility.

A range of high-quality antigens and antibodies to meet the needs for diagnostic immunoassay manufacturing.

END USERS/CUSTOMERS

IVD Kit Manufacturing Company

Incubated at BBB I RCB

Write Domain

NGIVD is driven by the '3Is' – Innovation, Indigenization, and Improvement – to develop high-quality, cost-effective diagnostic solutions across Clinical Chemistry, ELISA, Rapid Tests (Lateral Flow), and Molecular Diagnostics.

Application

RU-1 is serology based multiplex technology used for high-throughput, screening of tuberculosis using a single blood-based sample, including from dried blood spots.

COMPANY NAME
Nextgen Invitro Diagnostics Pvt Ltd.

DIRECTOR'S NAME
Pankaj Krishna

TRL- 8
Technology is developed and tested in blinded clinical trial.

INTELLECTUAL PROPERTY
Patent Granted

ABOUT THE TECHNOLOGY

RU-1 is a novel multiplex assay that detects multiple biomarkers of mycobacterium TB complex, enabling high sensitivity and specificity

Superior to Sputum Microscopy (50% sensitivity) while RU-1 targeting ~ 85% sensitivity and 90% specificity

Accuracy: Detects greater than 85% of all TB suspects

Accessibility : Can use Dried blood spots (DBS) for remote areas accessibility

Versatility: Just one sample is enough to test for all forms of TB

Efficiency: Can test upto 300 samples/day; can be increased to 1000 samples/day

PROBLEM ADDRESSED

RU-1 addresses a critical gap in tuberculosis (TB) diagnosis, especially in low-resource and high-burden settings. Traditional sputum microscopy has limited sensitivity (~50%). RU-1, a serology-based, bead-based multiplex assay, enables the simultaneous detection of multiple TB-specific biomarkers, offering significantly improved sensitivity (~85%) and specificity (~90%).
The technology allows testing from Dried Blood Spots (DBS), making it ideal for remote and underserved areas. Its ability to detect all forms of TB from a single sample, combined with high throughput (up to 1000 samples/day), positions RU-1 as a highly scalable, accessible, and accurate screening solution for TB control and elimination programs.

FUNDS RAISED/ACHIEVEMENTS

- BIRAC
- USISTEF

END USERS/CUSTOMERS

- Pathology lab
- Govt hospitals and health care centers
- Hospitals

Incubated at BBB I RCB
https://ngivd.com/

Bio Pharma

The startup focuses on developing biocompatible, nano-enabled herbal wound dressings that combine transdermal drug delivery, polymeric film technology, and nanoscience to promote faster healing and prevent infections.

Application

Provides a safe, affordable, and effective wound care solution that leverages plant-based healing agents and nanoscale delivery systems, ideal for resource-limited and infection-prone clinical settings.

COMPANY NAME	FOUNDERS' NAME
Kapardi Pharma Pvt Ltd	**Dr. DS Bakshi**
TRL- 4	**INTELLECTUAL PROPERTY** **After completion of project**

ABOUT THE TECHNOLOGY

This technology involves the development of a biocompatible transdermal polymeric film that delivers herbal oil and nanoactives in a controlled and sustained manner for wound healing applications.

The resulting film is flexible, breathable, and adherent to the skin, and is designed for once-in-three-day application, enabling sustained release of therapeutic agents at the wound site. The formulation and processing are scalable, cost-effective, and suitable for low-resource settings, making this technology a promising solution for chronic wounds, diabetic ulcers, and infection-prone skin injuries.

USP

- Dual-action nano-enhanced formulation
- Plant-based, biocompatible therapy
- Sustained release over 72 hours
- Stable film matrix technology
- Cost-effective and scalable
- Broad-spectrum antimicrobial activity
- Biodegradable and environmentally friendly
- Non-invasive and easy to apply
- Customizable formulation platform

PROBLEM ADDRESSED

- **Chronic wound infections**
- Frequent dressing changes
- Limited access to affordable, effective wound care in rural and low-resource settings
- Instability and poor retention of herbal oils when applied directly on wounds
- Low patient compliance
- Limited integration of natural therapies with advanced drug delivery in existing wound management options

FUNDS RAISED/ACHIEVEMENTS

- Self Funded

END USERS/CUSTOMERS

- Hospitals & Clinics
- Patients of Diabetic Wounds, Delayed healing wounds, Bed sores
- In rural or low-resource settings where affordable, easy-to-use wound care is critical.
- Military & Disaster Relief Organizations
- For field use in trauma or emergency settings where antimicrobial, no-refrigeration dressings are essential.
- For use in home-based wound care, especially in elderly or post-operative patients needing long-duration dressings.

Incubated at BBB I RCB
www.kapardipharma.com

Nutraceuticals

Solventless and full spectrum extraction of berberine

Application

Full spectrum berberine as a natural remedy for metabolic diseases

COMPANY NAME	FOUNDERS' NAME
Gramen Botanicals Pvt. Ltd.	Samarth Singh
TRL- 6	**INTELLECTUAL PROPERTY** Provision Patent filed

ABOUT THE TECHNOLOGY

We are using a membrane filtration technology to selectively extract different components from Berberis aristata root followed by reintegration to form a full spectrum berberine highly soluble product. This technology allows us to skip the use of chemicals and solvents that are common in the herbal extraction industry. This full spectrum formulation yields superior biological results compared to Berberine hydrochloride at a low manufacturing price point.

USP

- Solventless manufacturing
- Synergistic formulation inspired by traditional Medicine systems

PROBLEM ADDRESSED

Current berberine products are manufactured either using complex chemical modifications that involve chemical processing or using solvents , both of which leave the risk of residual impurities. We have devised a manufacturing method to make solvent less full-spectrum berberine product where the full spectrum nature allows synergistic interaction yielding superior solubility and biological benefits while beating competitors price points. This methodology can be extended to other herbal products also in future.

FUNDS RAISED/ACHIEVEMENTS

- Funded by internal profits from company's existing business

END USERS/CUSTOMERS

- The customers currently are ones suffering from metabolic indications especially Type 2 Diabates as well as population suffering from obesity.

Incubated at BBB I RCB
https://www.gramenbotanicals.com/

Medical Device

Early Intervention, Childcare

Application

A digital therapy platform making early vision intervention accessible and affordable for children with brain-based visual impairments, Cerebral Visual Impairment.

COMPANY NAME

Grailmaker Innovations

FOUNDERS' NAME

Prathyusha Potharaju
Vivian Manohar
Aishwarya Vijay

TRL- 6

INTELLECTUAL PROPERTY

Trademark Registered

ABOUT THE TECHNOLOGY

Vision Nanny is a web-based SaaS platform offering customizable, gamified therapy for children with Cerebral Visual Impairment (CVI). Built using VueJS, Firebase, and TensorFlow.js, it includes AI-based features for behavior-driven customization, pose and gaze tracking, and real-world object recognition. The platform simplifies therapy through personalized activities and therapist tools like assessment scales, child progress tracking, and remote delivery options, transforming traditional CVI intervention from costly, clinic-only setups to inclusive, home-based models.

USP

- CVI-specific SaaS platform with 50+ customizable, research-backed activities
- AI-based activity adaptation
- Device-agnostic (works on tablets, laptops, smart TVs, low-end devices)
- Cultural relevance, content tailored to regional contexts
- Affordable: $6.50/month vs. $400–$5000/year for traditional therapy
- Therapist tools: CVI-specific assessment scales
- Requires minimal bandwidth

Incubated at BBB I RCB

https://visionnanny.com/

PROBLEM ADDRESSED

CVI affects 36 million children globally, yet 80% go undiagnosed or untreated—especially in rural or resource-limited settings. Traditional therapy is expensive (~₹4 lakhs/year) and dependent on overburdened specialists. The current system is fragmented, inaccessible, and offers limited personalization. Vision Nanny addresses these challenges by decentralizing therapy, reducing cost by 50%, increasing therapy engagement by 3x, and allowing caregivers to deliver therapy directly with professional guidance.

FUNDS RAISED/ACHIEVEMENTS

- TIDE 2.0 Grant: Ministry of Electronics and Information Technology (MeitY)
- Optum Startup Studio Program
- Startup India Seed Fund Scheme (SISFS)
- Assistive Tech Grant: NCPEDP (India)
- Prathyusha is Forbes 30u30, Asia 2025 honoree in Social Impact

END USERS/CUSTOMERS

- 7000+ children impacted
- 3000+ users including LVPEI, Manipal Hospitals, Dr.Shroff Hospitals

Clean Label Diary Alternatives

Clean label, enzymatically transformed Oat milk made with proprietary stabilizer blend – affordable, scalable, and ready for multi-industry food application

Application

Used as a dairy-free beverage, in baking, cooking, RTD drinks and foodservice formulations

COMPANY NAME

DE3PBIO Technologies India Pvt. Ltd.

FOUNDERS' NAME

1. **DR. KAVISH KUMAR JAIN**
2. **PRIYANKA SRINIVAS**

TRL- 9

Product fully developed and operational in commercial settings.

INTELLECTUAL PROPERTY

- **AI-powered Charaka™ platform**
- **Proprietary natural stabiliser-emulsifier blend**
- **Enzyme-based formulation IP**

Commercialized with Country delight

ABOUT THE TECHNOLOGY

Our oat milk is developed using **Charaka™**, an AI-ML-powered R&D engine that enables rapid, cost-efficient, and clean-label food innovation. By leveraging enzyme transformation and a proprietary natural stabilizer-emulsifier blend, the formulation enhances protein digestibility, maintains a smooth creamy texture, and eliminates the need for artificial additives or E-number ingredients. This ensures a **100% vegan**, **naturally stabilized**, and **cost-effective** oat milk ideal for diverse food and beverage applications. The Charaka platform draws from over **1.5 million plant datasets**, allowing faster formulation with high success predictability and minimal CapEx.

USP

- Clean-label, no E-number emulsifiers or synthetic thickeners
- Natural stabilizers for smooth texture and shelf stability
- 100% vegan and allergen-free (no dairy, soy, gluten, egg)
- Enzymatically transformed for better nutrient absorption
- Cost-effective and scalable without CapEx
- Ideal for multi-format use: beverages, RTDs, bakery, sauces

PROBLEM ADDRESSED

Most oat milks in the market are either expensive, use synthetic stabilizers, or compromise on nutritional quality. They fail to cater to clean-label seekers and are often not adaptable across multiple food categories. Our solution addresses these issues by offering a scalable, clean-label, and cost-efficient oat milk that is free from artificial thickeners, preservatives, and allergens, designed for use across beverage, bakery, RTD, and foodservice sectors.

FUNDS RAISED/ACHIEVEMENTS

- NA

END USERS/CUSTOMERS

- Vegan and lactose-intolerant consumers
- Food and beverage brands (RTDs, alt-dairy)
- HoReCa and institutional kitchens
- Bakeries and plant-based dessert makers
- Nutraceutical and functional food formulators
- Private label manufacturers and distributors

Incubated at BBB I RCB

Insert website link

Food Technology

Antiflos@ rapid detection of antibiotics can be used for the detection and screening of antibiotics in milk sample

Application

on site, field level detection of antibiotics in milk using enzyme inhibition based colorimetric technology



COMPANY NAME	FOUNDERS' NAME
Florecer services Pvt Ltd.	Lalit Gupta & Renu Singh
TRL- 7	**INTELLECTUAL PROPERTY**
System prototype demonstrated in operational environment	Ongoing

ABOUT THE TECHNOLOGY

Florecer services pvt ltd. develops rapid diagnostics kits antibiotic in milk .
we have developed an innovative enzyme inhibition based colorimetric kit for rapid detection of antibiotic residue in milk.
if antibiotic are present, they inhibit a specific enzyme reaction, preventing the expected colour change
These are strip based kits, designed for easy field use with quick result & minimal training.

USP

- advanced, robust and easy to use
- can be applied directly under field conditions
- detects more than 50 antibiotics in milk during production and processing
- no extraction is required
- codex / EU Recommendation MRL
- cost effective , reproducible and sensitive technique
- validated with AOAC approved reference technology
- shelf stable with long usability

PROBLEM ADDRESSED

Undetected antibiotic residues in milk, resulting from veterinary drug use, pose serious health risks to consumers and can lead to non-compliance with food safety regulations. There is a critical need for low-cost, rapid, and on-site detection tools at dairy collection points to ensure milk safety and regulatory compliance.

FUNDS RAISED/ACHIEVEMENTS

- Pusa Krishi under Innovation and Agri-entrepreneurship program-RKVY-RAFTAAR, DAC & FW at Pusa Taksay Society, ZTM& BPD Unit, ICAR-IARI..
- Grant value- 20 Lakh

END USERS/CUSTOMERS

- Nestle.
- Amul.
- elsword organic food.
- Fssai, dairy cooperative.
- farmers and milk collection centres.

Incubated at BBB I RCB

www.florecers.com

Food Technology

Pestiflos@ rapid detection of pesticides can be used for the detection and screening of pesticides in so many agricultural commodities including milk and milk products, feed, Juices etc



Application

on site, field level detection of pesticide in fruits and vegetable , pulses & milk using enzyme inhibition based colorimetric technology

COMPANY NAME
Florecer Services Pvt. Ltd.

FOUNDERS' NAME
- Lalit Gupta
- Renu Singh

TRL- 7
System prototype demonstrated in operational environment

INTELLECTUAL PROPERTY
NA

ABOUT THE TECHNOLOGY

For routine monitoring of pesticides three stage assay has been developed on paper strip based on the principle of "enzyme inhibition". In case where analyte i.e. pesticides are absent, specific marker enzyme inherently present in the spores will act specifically on chromogenic substrate resulting in coloured end product on paper strip, whereas complete inhibition of marker enzyme takes place when pesticide present in the milk and milk products.

USP

- advanced, robust and easy to use
- universal kit for detection of pesticide residues
- can be applied directly under field conditions
- codex / EU Recommendation MRL
- cost effective , reproducible and sensitive & selective technique
- validated with AOAC approved reference technology
- simple and minimal extraction procedure
- result within 02 hour including extraction
- wide scope of application entire dairy and food chain
- shelf stable with long usability

Incubated at BBB I RCB

www.florecers.com

PROBLEM ADDRESSED

pesticide residues in food product & milk, water can cause serious health issues .
traditional lab tests are costly and slow.
there is a need for a quick, low cost, and field friendly method.
our kit provide rapid on site detection,supporting food safety and fssai compliance.

FUNDS RAISED/ACHIEVEMENTS

- Pusa Krishi under Innovation and Agri-entrepreneurship program-RKVY-RAFTAAR, DAC &FW at Pusa Taksay Society, ZTM& BPD Unit, ICAR-IARI..
- Grant value- 20 Lakh
- GOT FSSAI Order and approval

END USERS/CUSTOMERS

- Nestle
- Rufil
- Amul
- elsword organic food
- Fssai, dairy cooperative
- farmers and milk collection centres

Emerging Innovations

Cleantech

Organic121 Scientific Pvt. Ltd

Founders: Dr. Hemant Gupta

Wastewater treatment systems

DEVELOPS AND DELIVERS SUSTAINABLE INDUSTRIAL AND AGRICULTURAL TECHNOLOGY SOLUTION

- Wastewater treatment systems: ETP, STP, CETP, and FESTP
- Bio-energy solutions: biogas and bio-CNG plants
- Gas production facilities: oxygen and argon plants
- Organic / natural farming products and green chemistry platforms
- 100% Indian ownership — fully eligible under Make in Bharat initiative
- Integration of biotechnology with mechanical systems

Website: www.organic121.com

Social Impact

Innovationsatss Pvt Ltd - Shakti Wearables

SHAKTI
Fashion meets safety

Founders: Srishti Sharma

India's first women crime preventive device with patented non lethal electrocution and SOS technology

INDIA'S FIRST WOMEN'S CRIME PREVENTIVE DEVICE

- Patented non-lethal electrocution & SOS technology
- Problem solved: Enables immediate reaction to self-attack within seconds
- Target users: Women aged 13–62 across all economic backgrounds
- USP: First-of-its-kind device in India with patented non-lethal electrocution technology

NOTABLE ACHIEVEMENTS

- Funding: Raised through SISF Grant
- Recognition: Awarded Entrepreneur of the Year 2024 by Delhi Vidhan Sabha

Website: www.shaktiwearables.com

Emerging Innovations

Biopharma: Cell & Gene Therapy

Pro-Ortho Perfect India Pvt Ltd

Founders: Dr. Akshay A Zodge

Humable Orthopedic Aids Manufacturing Company

- **Company Focus**: Specializes in manufacturing high-quality orthopedic aids such as braces, supports, and assistive devices.
- **Technology & Innovation**: Utilizes advanced materials and modern manufacturing processes to ensure comfort, durability, and effectiveness.
- **Target Users:** Individuals suffering from musculoskeletal disorders, injuries, or chronic conditions.
- **Core Benefits:**
- Provides reliable and comfortable orthopedic aids.
- Helps in effective pain management.
- Supports faster recovery and rehabilitation.
- Enhances mobility and overall quality of life for patients.

Notable Achievements

- Raised Startup India Seed fund: Rs 25 Lakh

Website:https://humable.store.in/

Ayurvedic and Wellness

NaturoHabit Pvt Ltd

Founders: Swagatika Das,Gaurav Agarwal

Targeting Common Dermatological and Trichological Diseases using Natural Phytochemicals and its Nanoformulations: An In-vitro Approach

Dermatological skin ailments, Hair growth and Pityriasis Capitis

- **R&D Focus:** Discovery of phytochemically active biomolecules for dermatological & trichological applications.
- **Therapeutic Targets:** Atopic dermatitis, alopecia areata, pityriasis capitis & other common skin/hair disorders.
- **Validation Approach:** Efficacy testing through in-vitro disease models.
- **Product Philosophy:** Formulating natural & ayurvedic-based solutions for skin and hair health.
- **Target Consumers:** Individuals preferring natural & ayurvedic beauty regimes.
- Consumers seeking safer alternatives to chemical-laden products.
- **Value Proposition:** Holistic, effective, and sustainable solutions for healthier skin & hair.

Website: https://nathabit.in/

Emerging Innovations

Sustainable Orthopedic Implants Using Eco-Friendly PHB

DKS Incorporate

Founders: Sushma Sharma

Developing cost-effective, biodegradable orthopedic implants using eco-friendly PHB from agricultural byproducts

Biodegradable Orthopedic Implants from Agricultural Waste

- PHB-based polymer made from agri-waste using rhizobacteria
- 3D printed ligament screws, fracture screws & bone graft substitutes
- Eco-friendly & cost-effective alternative to conventional implants
- Biodegradable, avoids secondary removal surgeries
- Indigenous India-developed technology
- Customizable for patient-specific needs

NOTABLE ACHIEVEMENTS

- Funding: Raised through MSME IDEA HACKATHON 3.0 -15 Lakh

Website: dksincorporate.com

Healthcare

Bioheaven360 Genotec Pvt Ltd

Founders: Dr. Shailendra Vyas

India's first women crime preventive device with patented non lethal electrocution and SOS technology

AI-BASED LONGEVITY AND HEALTHY AGING PLATFORM (YOUVAN™)

Problem Addressed

- Tackling global longevity and healthy aging since 2018
- Goal: Help individuals achieve 100+ healthy, meaningful years
- Combines preventive + augmentative strategies via biotechnology

Technology

- AI-powered platform integrating multi-dimensional health data
- Deep phenotyping with 5,000+ data points (labs, vitals, genetics, imaging, lifestyle, etc.)
- Accessible at www.bioheaven360.com with direct health record upload & upcoming ABHA integration

USP

- Proprietary data assets
- POC completed, GTM-ready
- Advanced insights via LLM, NLP & AI/ML



Notable Achievements

- Secured ₹2 Cr funding
- DBT grantee with ₹0.67 Cr support

Website:https://www.bioheaven360.com/youvan/

Pioneering Ideas

Cleantech

Stratup Name: Bharat EcoLabs Pvt. Ltd.
Founder's Name: Ajinkya Pandey & Agnesh Pandey
Innovation: Development of a SynCom (ClariBio) for effective pollutant reduction in Packaged Sewage Treatment Plants (PSTPs)
TRL: 3

Agritech

Stratup Name: Bigbiological Pioneer Pvt. Ltd.
Innovators Name: Sunil Kurchania
Innovation: Revolutionizing Agriculture with Sustainable Biological Solutions Innovative Formulation research and product development
TRL: 3

Industrial Biotech

Stratup Name: Bharat Biomaterials LLP
Innovators Name: Sahaj Sarupria & Priyansh Kothari
Innovation: Sustainable Bio-Based Synthetic Leather Derived from Millet and Sugarcane Agro-Waste and Method for Its Preparation
TRL: 4

Industrial Biotech

Innovators Name: Prateek Yadav
Innovation: Yeast Extract from Brewer's Spent Yeast
TRL: 3

Diagnostics

Innovators Name: Dr. Jayanti Kumari
Innovation: OncoALERT - A rapid and field deployable Point-of-Care screening test for early detection of oral cancer
Achievements: Received BIRAC BIG-24 Grant
TRL: 4

Bio Pharma

Innovators Name: Kumar Nischaya
Innovation: SeptiCheck- a simple, rapid, low-cost, and validated method for simultaneously detecting last-resort drugs in the plasma of septic patients, utilizing high-performance liquid chromatography (HPLC)
TRL: 3

Nutraceuticals

Innovators Name: Vanshika
Innovation: Edible packaging from orange peel extract
TRL: 3

Nutraceuticals

Innovators Name: Dr. Nita Sharma Das
Innovation: NanoLift Cosmeceutical Composition for Anti-aging Skin, Hair and Eye Care based on Copper BindingPeptide, Fermented Bone Broth and Cellulose Nanofiber Mask
TRL: 3

Digital Healthcare

Innovators Name: Himanshu Rajpurohit
Innovation: Nexera.Health - Preventive mental Healthcare
TRL: 3

Pioneer ideas

Infrastructure Snapshot

BBB Facilities

Shared Wet Lab

Independent Labs

Infrastructure Snapshot

BBB Facilities

Central Instrumentation Facility

Culture Room

Infrastructure Snapshot

RCB Facilities

Experimental Animal House

BSL-3

Infrastructure Snapshot

RCB Facilities

Greenhouse



Advanced Technology Platform Centre

Events at Glance

Snapshot of key happenings

“Inauguration of BBB by Hon’ble Union Minister Dr. Jitendra Singh, Minister of State (Independent Charge), Ministry of Science & Technology”

Events at Glance

Snapshot of key happenings

"Visit of BBB by Dr. Jitendra Kumar, Member (Ex-officio) & Managing Director, Biotechnology Industry Research Assistance Council (BIRAC)"

Events at Glance

Snapshot of key happenings



Visit by Advisory Committee (Dr. Jitendra Singh MD BIRAC, Dr. Mrutyunjay Suar (DG, KIIT, Bhubaneswar), Dr. Ramjee Pallela (COO, CCMB, Hyderabad), and Dr. Chhaya Chauhan (Incubation Incharge, BIRAC)

Events at Glance

Snapshot of key happenings

"Interaction with Leaders: Dr. Renu Swarup, Geneticist and Former Secretary, Department of Biotechnology, Ministry of Science & Technology, Government of India"

Events at Glance

Snapshot of key happenings

***BioNEST E- YUVA* Conclave on 17.05.2024**

Events at Glance

Snapshot of key happenings

Visit by Delegates from Estonia

Visit by South African Delegates

Events at Glance

Snapshot of key happenings

Visit by the Foreign, Commonwealth and Development Office (FCDO)

BSC BioNEST Bio-Incubator

United Nations Educational, Scientific and Cultural Organization

क्षेत्रीय जैव प्रौद्योगिकी केन्द्र
Regional Centre for Biotechnology

BSC BioNEST Bio-Incubator (BBB), Regional Centre for Biotechnology (RCB)
3rd milestone, Faridabad - Gurgaon Rd, expressway, Faridabad, Haryana 121001

https://rcb.res.in/bbb-rcb/